Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

AVEO Pharmaceuticals Inc

+ Add to Watchlist

VPA:GR

2.034 EUR 0.173 7.84%

As of 15:44:18 ET on 05/22/2015.

Snapshot for AVEO Pharmaceuticals Inc (VPA)

Open: 1.899 Day's Range: 1.899 - 2.311 Volume: 33,064
Previous Close: 2.207 52wk Range: 0.460 - 3.023 1-Yr Rtn: +155.21%

Stock Chart for VPA

No chart data available.
  • VPA:GR 1.977
  • 1D
  • 1M
  • 1Y
2.207
Interactive VPA Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for VPA

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.7000
Est. PEG Ratio -
Market Cap (M EUR) 112.01
Shares Outstanding (M) 55.07
30 Day Average Volume 2,663
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/11/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for VPA

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for VPA

Aveo Pharmaceuticals Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing cancer therapeutics. The Company's lead product candidate is an oral inhibitor of the vascular endothelial growth factor, or VEGF,receptors.

Michael P BaileyPresident/CEOKeith S EhrlichChief Financial Officer
Michael N NeedleChief Medical Ofcr:Aveo OncologyJoseph VittiglioSenior VP/General Counsel
More Company Profile & Key Executives for VPA

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil